Macrophages and HIV infection: Therapeutical approaches toward this strategic virus reservoir

Antiviral Research

Volumn 55, Issue 2, 2002, Pages 209-225

  Aquaro, Stefano ^a   Caliò, Raffaele ^a   Balzarini, Jan ^b   Bellocchi, Maria Concetta ^c   Garaci, Enrico ^a,d   Perno, Carlo Federico ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Antiviral; CD4 lymphocytes; Drugs; HIV infection; Macrophages; Therapy

Indexed keywords

1 (NAPHTHOXYACETYL)HISTIDYL(5 AMINO 6 CYCLOHEXYL 3,4 DIHYDROXY 2 ISOPROPYLHEXANOYL)ISOLEUCINE N (2 PYRIDYLMETHYL)AMIDE; ACYCLIC NUCLEOSIDE; ADEFOVIR; ANTIRETROVIRUS AGENT; CF 1001; CF 1093; CF 1109; CF 1221; CHEMOKINE; DELAVIRDINE; EFAVIRENZ; INDINAVIR; KYNOSTATIN 272; M 40401; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NEVIRAPINE; NUCLEOSIDE ANALOG; PHOSPHONIC ACID DERIVATIVE; PHOSPHORAMIDIC ACID DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SO 221; SO 324; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; APOPTOSIS; CELL METABOLISM; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE ACTIVATION; MACROPHAGE; NERVE CELL; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TARGET CELL; TREATMENT FAILURE; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; HIV; HIV INFECTIONS; HUMANS; MACROPHAGES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0036289210     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00052-9     Document Type: Review

References (121)

1. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity
2. The binding subunit of pertussis toxin inhibits HIV replication in human macrophages and virus expression in chronically infected promonocytic U1 cells
3. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1
4. HIV coreceptor downregulation as antiviral principle: SDF-1α-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication
5. Human macrophages sustain high-levels of HIV-1 replication in long-term cultures under antiviral treatment
6. Clinical implications of HIV dynamics and drug resistance in macrophages
7. The LD78β isoform of MIP-1α is the most potent CC-chemokine in inhibiting CCR5-dependent HIV-1 replication in human macrophages
8. Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes
9. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes
10. M40401, a SOD mimetic compound with a potent anti-HIV activity in macrophages, prevents apoptosis in astrocytes
11. Activity of masked 2′-3′-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages
12. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
13. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor
14. Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo
15. CycloSaligenyl-2′,3′-didehydro-2′,3′-dideoxythymidine monophosphate (CycloSal-d4TMP): Efficient intracellular delivery of d4TMP
16. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxypropyl)-2-6-diaminopurine against human immunodeficiency virus in different human cell systems
17. Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues
18. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds
19. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides: A comparison with their parental 2′,3′-dideoxyribonucleosides
20. Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives
21. Intracellular metabolism of cyclosaligen 3′-azido-2′,3′-dideoxythymidine monophosphate, a prodrug of 3′-azido-2′,3′-dideoxythymidine (zidovudine)
22. The challenge of viral reservoirs in hiv-1 infection
23. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
24. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
25. Latent reservoirs of HIV: Obstacles to the eradication of virus
26. Identification of RANTES, MIP-1alpha, and MIP-1beta major HIV-suppressive factors produced by CD8+ T cells
27. Full-length recombinant CD4 and recombinant gp120 inhibit fusion between HIV infected macrophages and uninfected CD4-expressing T-lymphoblastoid cells
28. Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury
29. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immudeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance development
30. Reverse transcriptase inhibitors as anti-HIV drugs
31. Strategies in the design of antiviral drugs
32. A novel selective broad-spectrum anti-DNA agent
33. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines
34. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists
35. Engineered erythrocytes as carriers and bioreactors
36. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry
37. Current evidence and future directions for targeting HIV entry: Therapeutic and prophylactic strategies
38. Viral dynamics in HIV-1 infection
39. A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus
40. New drug combinations for the treatment of murine AIDS and macrophage protection
41. Inhibition of murine AIDS by alternate administration of azidothymidine and fludarabine monophosphate
42. Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS
43. Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV
44. Intracellular GSH content and HIV replication in human macrophages
45. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes
46. Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxyuridine-5′-triphosphate
47. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults
48. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4
49. Electron microscopic observation of the aggregation of membrane proteins in human erythrocyte by melittin
50. HIV-1 in blood monocytes: Frequency of detection of proviral DNA using PCR and comparison with the total CD4 count
51. Two inflammatory mediator cytokine genes are closely linked and variably amplified on chromosome 17q
52. Oligomeric structure and anion transport function of human erythrocyte band 3 protein
53. Effect of β-chemokines on human immunodeficiency virus type 1 replication, binding, uncoating, and CCR5 receptor expression in human monocyte-derived macrophages
54. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells
55. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy
56. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy
57. Reduction in hospitalization costs, morbidity, disability, and mortality in patients with aids treated with protease inhibitors
58. The mobility of intramembrane particles in non-haemolysed human erytrocytes. Factors affecting acridine-orange-induced particle aggregation
59. Lamivudine in children with human immunodeficiency virus infection: A phase I-II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group
60. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates
61. Seminars in medicine of he Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency
62. Structured treatment interruptions for the management of HIV infection
63. Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes
64. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity
65. Human red blood cells as bioreactors for the release of 2′,3′-dideoxycytidine, an inhibitor of HIV infectivity
66. Intracellular expression of p170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients
67. Correlation between induction of lymphocyte apoptosis and prostaglandin E2 production by macrophages infected with HIV
68. Mononuclear phagocytes of blood and bone marrow: Comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections
69. Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease
70. The LD78β isoform of MIP-1α is the most potent CCR5 agonist and HIV-1-inhibiting chemokine
71. Oxidative stress and neuroAIDS: Triggers, modulators and novel antioxidants
72. The contribution of oxidative stress in apoptosis of human cultured astroglial cells induced by supernatants of HIV-1 infected macrophages
73. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease
74. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice
75. Structures of human genes coding for cytokine LD78 and their expression
76. A cDNA clone used to study mRNA inducible in human tonsillar lymphocytes by a tumor promoter
77. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors
78. Macrophages as a source of HIV during opportunistic infections
79. Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: An ultrastructural study
80. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects
81. Glutathione inhibits HIV replication by acting at late stages of the virus life cycle
82. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
83. Decay characteristics of HIV-1-infected compartments during combination therapy
84. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine
85. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages
86. Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools and cytokines
87. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages
88. Selective delivery and efficacy of Fludarabine encapsulated in red blood cells to HIV-infected macrophages
89. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus
90. Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: Efficiency metabolism and activity against human immunodeficiency virus or herpes simplex virus
91. Cells non-productively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency
92. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection
93. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1α
94. Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process
95. Evaluation of biochemical changes during in vivo erythrocyte senescence in the dog
96. Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir
97. Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus
98. Peroxynitrite decomposition catalyst: Therapeutics for peroxynitrite-mediated pathology
99. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats
100. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity
101. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy
102. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
103. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
104. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy
105. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor
106. 2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor
107. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages
108. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication
109. Epidermal Langerhans cells a target for HTLV-III/LAV infection
110. Clustering of integral membrane proteins of the human erythrocyte membrane stimulates autologous IgG binding, complement deposition, and phagocytosis
111. Characterization of the autologous antibodies that opsonize erythrocytes with clustered integral membrane proteins
112. Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1
113. A model of human immunodeficiency virus encephalitis in scid mice
114. Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex
115. Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression
116. Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor
117. Cellular anion transport
118. Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: Implications for the neuropathogenesis of AIDS
119. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro
120. 2-terminal heterogeneity. Functional comparison of different natural isoforms
121. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy